Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK002 open-label pilot study in antihistamine-resistant chronic urticaria
2017-002581-51Phase 2Completed
- Sponsor
- Allakos Inc.
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lirentelimab in chronic urticaria (CU), sponsored by Allakos Inc. Primary endpoint: Change in Urticaria Control Test score. Started Sep 2017; status: completed.
02
Drugs
lirentelimab
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on 2017-002581-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002581-51.